Edwards SAPIEN 3 Ultra transcatheter heart valve
Learn about the SAPIEN 3 Ultra valve, a balloon-expandable transcatheter heart valve designed for aortic stenosis patients. See how it offers excellent paravalvular leak performance, coronary access, and future treatment options.
Real-World Experience With the SAPIEN 3 Ultra Transcatheter Heart Valve …
2021年8月26日 · The SAPIEN 3 Ultra (Ultra) is a new generation balloon-expandable transcatheter heart valve with a modified external skirt that is designed to reduce PVR, but reports of clinical and echocardiographic outcomes are limited.
Valve-in-Surgical-Valve With SAPIEN 3 for Transcatheter Aortic Valve ...
2021年5月18日 · Clinical outcomes of valve-in-valve–transcatheter aortic valve replacement using the latest SAPIEN 3 valve had excellent outcomes. Excellent outcomes were also observed in patients with non–high-risk patients, indicating the feasibility of expanding this technique into lower-risk patients.
Edwards SAPIEN 3 transcatheter heart valve | Edwards Lifesciences
Learn about the Edwards SAPIEN 3 valve, the only valve approved for valve-in-valve procedures in both aortic and mitral positions. See the valve design, indications, contraindications, and warnings.
SAPIEN 3 Ultra transcatheter heart valve | Edwards Lifesciences
The Edwards SAPIEN 3, SAPIEN 3 Ultra, and SAPIEN 3 Ultra RESILIA Transcatheter Heart Valve system is indicated for patients with symptomatic heart disease due to failing (stenosed, insufficient, or combined) of a surgical or transcatheter bioprosthetic aortic valve, a surgical bioprosthetic mitral valve, or a native mitral valve with an ...
The Edwards SAPIEN 3 Ultra transcatheter heart valve system is indicated for relief of aortic stenosis in patients with symptomatic heart disease due to severe native calcific aortic stenosis who are judged by a Heart Team, including a cardiac surgeon, to be appropriate for the transcatheter heart valve replacement
2023年3月18日 · The Edwards SAPIEN 3, SAPIEN 3 Ultra, and SAPIEN 3 Ultra RESILIA transcatheter heart valve system is indicated for use in patients with heart disease due to native calcific aortic stenosis at any or all levels of surgical risk for open heart surgery.
Valve-in-valve–transcatheter aortic valve replace-ment is safe and effective in high-risk patients with a deteriorated surgical bioprosthetic valve. The number of valve-in-valve–transcatheter aortic valve replacements performed is growing. WHAT THE STUDY ADDS.
Transcatheter SAPIEN 3 Ultra RESILIA | Edwards Lifesciences
The SAPIEN 3 Ultra RESILIA valve is a transcatheter heart valve with advanced calcium-blocking tissue technology that may improve valve longevity and reduce reintervention. It is indicated for relief of aortic stenosis and for patients with failing bioprosthetic or native valves.
Backed by landmark clinical evidence, the SAPIEN 3 transcatheter heart valve is designed to minimise the risk of complications, providing a proven clinical experience for your patients and your evolving TAVI program. Simple. Reduced procedural complexity with simplified access, and deployment. Low-Profile.